Patents Assigned to Universite de Strasbourg
  • Patent number: 11499155
    Abstract: The present disclosure relates to an inhibitor of Dynamin 2 for use in the treatment of centronuclear myopathies. The present disclosure relates to pharmaceutical compositions containing Dynamin 2 inhibitor and to their use for the treatment of centronuclear myopathies. It also deals with a method for identifying or screening molecules useful in the treatment of a centronuclear myopathy.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: November 15, 2022
    Assignees: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Jocelyn Laporte, Belinda Cowling, Hichem Tasfaout
  • Patent number: 11434490
    Abstract: RNA aptamers are disclosed with distinct fluorescent properties, fluorophore binding affinities, and salt dependence. Also disclosed are corresponding fluorophores, with selected fluorophores evidencing high cellular permeability. The aptamer's high fluorophore affinities, the high brightness of the bound complexes, and their thermal and salt stability, provide distinct aspects of the disclosed aptamers.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: September 6, 2022
    Assignees: Centre National De La Recherche, Scientifique Université De Strasbourg, Simon Fraser University, The United States of America, As Represented by The Secretary, Department of Health and Human Services
    Inventors: Michael Ryckelynck, Alexis Autour, Peter Unrau, Elena Dolgosheina, Sunny Chiu Yuk Jeng, Shanker Shyam Sundhar Panchapakesan, Amir Abdolahzadeh, Razvan Cojocaru, Adrian Ferré D'Amaré, Robert Trachman
  • Patent number: 11434882
    Abstract: Disclosed is a device including at least one circulating zone and at least one fluid including at least one more-paramagnetic liquid and at least one less-paramagnetic liquid forming a liquid-liquid interphase, the device including at least one element generating, in the circulating zone, a magnetic field, wherein the less-paramagnetic liquid is surrounded by the more-paramagnetic liquid in the circulating zone or wherein the more-paramagnetic liquid is surrounded by the less-paramagnetic liquid in the circulating zone. Also disclosed is a method including circulating at least one less-paramagnetic liquid inside one or more circulating zones of a device including at least one circulating zone and at least one more-paramagnetic liquid in the circulating zone.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: September 6, 2022
    Assignees: UNIVERSITÉ DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH COLLEGE GREEN
    Inventors: Thomas Hermans, John Michael David Coey, Peter Dunne, Bernard Doudin
  • Patent number: 11434253
    Abstract: Enantiopure terphenyl presenting two ortho-located chiral axes having the following structural formula (I): their process of synthesis and their use as mono or bidentate ligands for asymmetric organometallic reactions, as organocatalysts, as chiral base and as generator, with metal, of isolable chiral metallic complexes for applications in asymmetric catalysis and others.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: September 6, 2022
    Assignees: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Quentin Dherbassy, Joanna Wencel-Delord, Françoise Colobert, Gaspard Hedouin
  • Patent number: 11365251
    Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs).
    Type: Grant
    Filed: October 27, 2020
    Date of Patent: June 21, 2022
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Strasbourg, Chu Strasbourg, Les Hôpitaux Universitaires de Strasbourg
    Inventors: Thomas Baumert, Rajeevkumar Tawar
  • Patent number: 11357719
    Abstract: Disclosed are a method for preparing a hydroalcoholic extract obtained from a biomass of the shoots of a plant from the family of Plumbaginaceae, a butanol extract of Armenia maritima, a method for the preparation thereof, the use thereof, and compositions containing same.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: June 14, 2022
    Assignees: BIOTECHMARINE, SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, L'UNIVERSITE DE STRASBOURG
    Inventors: Lorène Gourguillon, Laetitia Cattuzzato
  • Patent number: 11332503
    Abstract: The present invention relates to peptides for the treatment or prevention of diabetes mellitus and associated disorders.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: May 17, 2022
    Assignees: UNIVERSITE DE STRASBOURG, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), VAXINE PTY LTD
    Inventors: Vincent Marion, Nikolai Petrovsky
  • Patent number: 11282978
    Abstract: The invention relates to a method for manufacturing a semiconductor component comprising a thin layer of crystalline silicon on a substrate, comprising the steps of: providing a silicon-rich aluminum substrate (S0), depositing a thin layer of amorphous silicon on the substrate (S1), and applying thermal annealing (S2) to the thin layer of amorphous silicon to obtain a thin layer of crystalline silicon on the substrate.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: March 22, 2022
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE STRASBOURG
    Inventors: Abdelilah Slaoui, Pierre Bellanger, Alexander Ulyashin, Freddy Syvertsen
  • Patent number: 11267947
    Abstract: A method for modifying a cellular polymer foam with apparent porosity, which includes providing a cellular polymer foam with apparent porosity, placing the cellular polymer foam in contact with at least one compound in order to obtain a cellular polymer foam including on the surface thereof an intermediate phase formed from the compound having at least one catechol unit. The foam may be used as a catalyst substrate.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: March 8, 2022
    Assignees: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE CLAUDE BERNARD LYON 1
    Inventors: David Edouard, Vincent Ritleng, Loïc Jierry, Nguyet Trang Thanh Chau Dalencon
  • Patent number: 11236132
    Abstract: The present invention relates to novel fusion polypeptides and the uses thereof. The invention particularly relates to conjugated coat proteins derived from nepoviruses, virus-like particles made with such proteins, and the uses thereof. The particles of the invention can expose and/or encage molecules of interest and have utility in various fields such as the pharmaceutical, agro, or veterinary areas.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: February 1, 2022
    Assignees: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Lorène Belval, Gérard Demangeat, Caroline Hemmer, Christophe Ritzenthaler
  • Patent number: 11236303
    Abstract: The invention relates to a method of producing CD34+CD4dim megakaryocyte (MK) progenitor cells, and substantially pure cell population of megakaryocyte precursor cells obtained by said method. The invention also relates to a method of producing proplatelet-bearing MKs and/or platelets using the CD34+CD4dim cells.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: February 1, 2022
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ETABLISSMENT FRANçIS DU SANG, UNIVERSITÉ DE STRASBOURG
    Inventors: Catherine Strassel, Christian Gachet, François Lanza, Nathalie Brouard
  • Patent number: 11224386
    Abstract: A method for determining a configuration setting of a source of ionizing radiation reducing a radiation dose absorbed by a patient and a practitioner in a medical operating room during a procedure. Prior to the procedure a database of maps of simulated propagation and scattering of ionizing radiation in a model of the medical operating room is obtained for different configuration settings. During the procedure, a position of the practitioner is determined. After determining a set of configuration settings of the source enabling the production of an image of a target anatomical structure a radiation dose absorbed by the patient and the practitioner is determined using the maps from the database. A recommended configuration setting for which a combined radiation dose is reduced is then outputted.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: January 18, 2022
    Assignees: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS-
    Inventors: Nicolas Padoy, Nicolas Loy Rodas, Michel de Mathelin, Julien Bert, Dimitris Visvikis
  • Patent number: 11180606
    Abstract: A polyester polyol of formula produced by a first polycondensation (a) of a sugar alcohol Z in C3 to C8 and two diacids Y and Y? which are the same or different in C4 to C36, and a second polycondensation (b) of the product produced in (a) with two diols X and X? which are the same or different in C2 to C12, the polymer including such a polyester polyol. Also, a method for producing the polyester polyols and the use thereof in foams, adhesives, coatings or elastomers of polyurethane or polyisocyanurate.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: November 23, 2021
    Assignees: TEREOS STARCH & SWEETENERS BELGIUM, CENTRE NATIONAL DE LA RECHERCHE SCIEN'I'IFIQUE, SOCIÉTÉ SOPREMA SAS, UNIVERSITÉ DE STRASBOURG
    Inventors: Pierre Etienne Bindschedler, Alexandru Sarbu, Stephanie Laurichesse, Remi Perrin, Pierre Furtwengler, Luc Avérous, Andreas Redl
  • Patent number: 11181521
    Abstract: The present invention relates to a method for capturing a molecular target present in the aqueous phase of a water-in-oil emulsion, said method being based on the use of a binding system comprising (a) a surfactant bearing a functional moiety on its hydrophilic head group and (b) a chemoprobe that acts as a molecular staple between the functionalized surfactant and the molecular target and comprises at least two distinct domains namely (i) at least one capture moiety which is able to specifically bind the molecular target and (ii) at least one binding domain which is able to interact with the functional group of the surfactant through covalent or non-covalent interactions, directly or through a binding intermediary.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: November 23, 2021
    Assignees: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE INTERNATIONAL DE RECHERCHE AUX FRONTIÈRES DE LA CHIMIE
    Inventors: Alain Wagner, Sylvain Ursuegui, Michael Ryckelynck, Ketty Pernod, Andrew David Griffiths
  • Patent number: 11156840
    Abstract: An optical guide for a near-eye display device includes a first guide element having a light input zone and a second guide element having an output zone. The first guide element is superimposed on the second guide element. The optical guide also includes an optical coupling system between the first guide element and the second guide element, and the first and second guide elements have, on the first part of their length, a mutual spacing so as to delimit a thin layer of air between said guide elements extending between a first longitudinal end of the guide elements and the optical coupling system. The optical coupling system, located at a second longitudinal end of the first and second guide elements, includes a single-piece portion of the guide elements, associated with an optical reflection member to propagate the beams of light from the input zone toward the output zone.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: October 26, 2021
    Assignees: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DES SCIENES APPLIQUEES
    Inventors: Jianming Yang, Patrice Twardowski, Joël Fontaine
  • Patent number: 11147332
    Abstract: A protective helmet includes an inner cap, an outer cap and a decoupling layer capable of allowing the outer cap to rotate relative to the inner cap about any axis of rotation in the event of an impact. At least one spherical surface is completely contained in the decoupling layer. The helmet includes a fastening strap attached at two opposing points of the inner cap without any mechanical connection with the outer cap. The strap is intended to fasten the helmet to the head of the wearer. The helmet includes a fastening frame attached to the inner cap, and the strap is attached to the inner cap by the fastening frame.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: October 19, 2021
    Assignees: UNIVERSITÉ DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventor: Rémy Willinger
  • Publication number: 20210309964
    Abstract: The present invention provides a simple and robust human liver cell-based system in which persistent hepatitis C infection, persistent hepatitis B infection or ethanol exposure induces a clinical Prognostic Liver Signature (PLS) high-risk gene signature. The cellular model system for hepatocellular carcinoma (HCC)/cirrhosis development and progression may be used in the screening of compounds useful in the treatment and/or prevention of cirrhosis and/or HCC as well as in the identification biomarkers for the prediction of liver disease (especially cirrhosis) progression and HCC. The present invention also relates to specific compounds that have been identified, using such screening methods, as useful in the treatment and/or the prevention of HCC/cirrhosis.
    Type: Application
    Filed: April 22, 2021
    Publication date: October 7, 2021
    Applicants: Universite de Strasbourg, Institut National de la Sante et de la Recherche Medicale, Institut Hospitalier Universitaire de Strasbourg, ICAHN School of Medicine at Mount Sinai
    Inventors: Thomas Baumert, Yujin Hoshida
  • Publication number: 20210246254
    Abstract: A rigid foam or composition allowing a rigid foam to be obtained made from polyurethane and/or polyisocyanurate. The rigid foam or composition includes polyols selected from polyester polyols and polyether polyols; the polyols include: 5 to 50% of a polyester polyol A by weight relative to the total weight of the polyols; and a polyol B selected from polyester polyols B and polyether polyols B. The polyester polyol A is of general formula Rx-Ry-Z-Ry?-Rx? in which Z is a C3 to C8 alcohol sugar chosen from glycerol, sorbitol, erythritol, xylitol, araditol, ribitol, dulcitol, mannitol and volemitol. Ry and Ry? are diesters of formula —OOC—Cn-COO— in which n is between 2 and 34, and Rx and Rx? are identical or different C2 to C12 monoalcohols.
    Type: Application
    Filed: January 22, 2019
    Publication date: August 12, 2021
    Applicants: TEREOS STARCH & SWEETENERS BELGIUM, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, SOPREMA, UNIVERSITÉ DE STRASBOURG
    Inventors: Pierre Etienne BINDSCHENDLER, Alexandru SARBU, Rémi PERRIN, Pierre FURTWENGLER, Luc AVÉROUS, Andréas REDL
  • Publication number: 20210221784
    Abstract: The invention relates to compounds, pyridine derivatives, and pharmaceutical 10 compositions containing same for use in the treatment of pain. It also relates to specific compounds, compositions comprising the same and uses thereof, in particular in the treatment of pain.
    Type: Application
    Filed: February 5, 2019
    Publication date: July 22, 2021
    Applicants: Université de Strasbourg, Centre National de la Recherche Scientifique
    Inventors: Martine SCHMITT, Jacques BRICARD, Frédéric SIMONIN, Jean-Jacques BOURGUIGNON, Frédéric BIHEL, Khadija ELHABAZI
  • Patent number: 11046657
    Abstract: A subject of the present invention is a compound having the general formula (I): a pharmaceutically acceptable salt thereof or a tautomeric form thereof, wherein A, B3, B4, B5, Y, X, B1 and B2 are as defined in any one of claims 1 to 10. Another subject of the invention is the compound as defined above for use as a medicament, in particular for preventing and/or treating inflammation and inflammatory diseases, immune and auto-immune diseases, pain related diseases, genetic diseases and/or cancer.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: June 29, 2021
    Assignees: Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale, Universite de Strasbourg, Universite Paris-Sud, Centre International de Recherche aux Frontieres de la Chimie
    Inventors: Dominique Bonnet, Nelly Frossard, Jean-Luc Galzi, Christophe Guignabert, Marcel Hibert, Frédéric Simonin, Sylviane Muller